Maintaining ductus arteriosus patency by the percutaneous placement of coronary artery stents provides an alternative to surgical systemic-to-pulmonary artery shunts. This maintains pulmonary blood flow and serves as a temporary bridge towards later surgical repair. Since the first report by Gibbs, et al. in 1992, the success and outcome of ductal stenting have improved due to advances in technique and equipment. This is now considered an acceptable option for these patients in many centres.
INTRODUCTION
Cyanotic congenital heart disease with duct-dependent pulmonary blood flow is a life threatening condition. Typical lesions include pulmonary and tricuspid atresia, critical pulmonary stenosis and tetralogy of Fallot. Establishing adequate pulmonary blood flow is essential for survival in these patients and early intervention is often required.
This may be accomplished by using intravenous prostaglandin therapy to maintain duct patency until surgical intervention is possible (palliation or complete repair). Surgical options may, however, be limited by centre experience and patient factors such as critical illness and very low birth weight. Surgical palliation consists of a systemic-to-pulmonary artery shunt as a first stage procedure.
Although this has been used since the mid 1940s, it is still associated with significant morbidity and mortality. (1, 2) Complications such as shunt thrombosis, pleural fluid collections and nerve injury with diaphragmatic paralysis have been described. (3, 4) Ongoing problems include progressive endovascular growth with obstruction, distortion and differential growth of the branch pulmonary arteries, as well as adhesions which may complicate future surgeries. Winter 2013
Volume 10 • Number 3 the procedure and were reported in only 2 studies: acute stent thrombosis (n=1), (14) pulmonary haemorrhage (n=1) and retroperitoneal haemorrhage secondary to an underlying coagulopathy (n=1). (15) Early re-intervention within the same admission consisted of mostly duct re-stenting. In most cases this was necessary to overcome early significant constriction as a result of unstented ductal segments. Deaths before discharge (not including deaths related to the procedure) were few and unrelated to stent implantation. These were mostly due to nosocomial sepsis and respiratory complications.
Mid-to-long term outcomes of PDA stenting
The majority of studies followed up on patients at 6 months postprocedure. Follow-up intervals were scheduled to detect stent occlusion. A summary of the mid-to-long term outcomes of PDA stenting can be seen in Table 2 . (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) Progressive stent stenosis (15) was reported in a few cases. These cases were either re-stented or a balloon angioplasty was performed. Where this was not successful in improving systemic saturations, surgery was carried out. Spon- A small number of deaths were reported at follow-up and occurred between the time of initial discharge and before the first surgery was performed. These were mainly attributed to sepsis and pneumonia in most cases and unrelated to the PDA stent.
At first surgery (including systemic-to-pulmonary artery shunts, cavopulmonary shunts and complete repair), reported pulmonary artery growth was reasonable in all studies. The effect of PDA stenting on the anatomy of the branch pulmonary arteries is still unclear. Early on a significant number of cases required pulmonary arterioplasty. Lately most studies reporting on complications at first surgery found that most stents were easily removed with very few patients requiring reconstruction for pulmonary artery distortion. As a matter of fact, it seems that pulmonary artery growth is promoted by PDA stenting. It has been postulated that since a stent is implanted in the natural position of a duct, this may result in a better angle between the PDA and the branch pulmonary arteries, allowing for improved growth.
TECHNICAL ASPECTS
The procedure is usually performed under general anaesthesia or deep conscious sedation. In our practice, all patients are discussed beforehand with the cardiothoracic team and surgical standby is routinely available. In order to facilitate stent placement, it is preferable to have a mildly constricted duct (enough to allow the stent to be secured). It is therefore recommended to stop prostaglandin infusion 6 -12 hours before the procedure. However, Various catheters may be utilised for angiography and stent. Routine angiography is usually performed with a pigtail catheter followed by selective and detailed angiography. We prefer to do angiograms in close approximation to the ductal origin and use an array of catheters for example: right Judkins, Cobra, Multipurpose (Cordis, Roden, Netherlands). In the majority of cases, the configuration of a right coronary artery catheter should enable one to cross the duct safely, but sometimes a cut-off pigtail may be useful to cross the PDA. In difficult cases a coaxial system may be extremely helpful. (16) In our experience, the ductal tissue in some of these PDAs may be quite sensitive and prone to spasm. We therefore routinely use a microcatheter with a very soft guide wire e.g. longer than the ductus after taking these facts into account. Some stent protrusion into the aorta and pulmonary artery (1 -2mm) is acceptable. We keep to the stent sizes as recommended by Alwi (3) : 3.5 mm diameter in those patients weighing <3kg, 4mm in those weighing 3 -5kg, and 4.5mm stents in those patients weighing 5kg and above.
If patients are ventilated, they should be extubated as early as possible. Heparin infusion is continued at a dose of 25U/kg/hr for 24 -48 hours. Aspirin is simultaneously initiated at 2 -3mg/kg/day and patients are discharged on this dose.
GENERAL COMMENTS
As we gained experience with the technique, we now deliver stents bare without using a guiding catheter/long sheath especially in 
LIMITATIONS OF PDA STENTING
The most frequently reported limitations include technical problems related to patient size (e.g. prematurity) and duct morphology.
Numerous variations of PDA anatomy have been described and may affect the success of stent delivery. Lesions with a higher success rate include pulmonary atresia with ventricular septal defect (VSD) and tricuspid atresia as these are associated with a simpler duct anatomy. Pulmonary atresia with intact ventricular septum is often associated with long, tortuous ducts with multiple areas of stenoses. (4) Therefore, complicated duct anatomy is a contraindication to stent placement. (11) Branch pulmonary artery stenosis is aggravated by PDA stenting and this should therefore also be avoided. (3) Other reported peri-procedural complications include acute stent thrombosis (2 -3%), pre-stent ductal spasm (<1%), stent dislodgement and migration, vessel or chamber perforation and neointimal proliferation of which the overall incidence is low. (3, 8, 11, 12, 14) Long term complications resemble those of surgical shunts and consist of progressive stent stenosis, pulmonary overflow with pulmonary hypertension and branch pulmonary artery distortion.
PDA STENTING
FIGURE 3: Result of an incomplete ductal stent placement
The short arrow points towards a stenotic ductal segment resulting from incomplete ductal covering becoming apparent 7 days after initial stent placement. Note the acute angle and extreme stenosis of the remaining ductal tissue at the aortic origin of the PDA. This was eventually crossed using a cut-off pigtail catheter and a co-axial system. Longer arrow demonstrates a contrast filled nasogastric tube used as a marker for stent delivery. Asterisk shows patent original stent in situ.
